Adavosertib - AstraZeneca

Drug Profile

Adavosertib - AstraZeneca

Alternative Names: AZD 1775; L001739996-008U; MK-1775 hemihydrate; MK1775

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Washington
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidinones; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
  • Phase I Colorectal cancer; Glioblastoma; Haematological disorders; Head and neck cancer; Uterine cancer; Vulvovaginal cancer
  • Preclinical Diffuse large B cell lymphoma
  • Discontinued Cervical cancer

Most Recent Events

  • 31 Oct 2018 New York University School of Medicine plans a phase II trial for Acute myeloid leukaemia, Myelodysplastic syndrome and Myelofibrosis (Late stage disease; Monotherapy, Combination therapy), in November 2018 (NCT03718143)
  • 12 Sep 2018 AstraZeneca plans a phase II trial for Uterine cancer (Second-line therapy or greater, Recurrent) in USA (PO) in October 2018 (NCT03668340)
  • 04 Sep 2018 Phase-II clinical trials in Endometrial cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT03660826)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top